Ozari vs Calibrate: Which GLP-1 Program Delivers Better Weight Loss Outcomes?

When Sarah's Calibrate account suddenly went dark in September 2024, she was eight months into her weight loss journey and down 42 pounds on semaglutide. The abrupt closure left her scrambling to find a new provider, refill her prescription, and maintain the momentum she'd worked so hard to build. She wasn't alone—thousands of Calibrate patients found themselves in the same situation, searching for affordable GLP-1 programs that could deliver similar results without the premium price tag or uncertainty.

The telehealth weight loss space has changed dramatically over the past year. Programs that seemed untouchable have shuttered, while newer platforms offering compounded GLP-1 medications have stepped in to fill the gap. If you're choosing between providers or looking for a Calibrate alternative, understanding the actual outcomes, costs, and support structures matters more than marketing promises.

What Happened to Calibrate and Why It Matters

Calibrate launched in 2020 with significant venture capital backing and a promise to transform metabolic health through a combination of GLP-1 medications and lifestyle coaching. At its peak, the company served tens of thousands of patients and charged between $135 to $165 per month for their program, plus the cost of medication—which often ran $900 to $1,300 monthly without insurance coverage.

In September 2024, Calibrate abruptly ceased operations. The closure wasn't gradual or planned—patients received little warning, and many were left without access to their medical records, prescription histories, or ongoing care coordination. The company cited "challenging market conditions" and difficulties with insurance reimbursement models, but the impact on patients was immediate and, frankly, devastating.

We've seen dozens of former Calibrate patients in our practice since then. The recurring theme? They valued the medication access and appreciated the coaching, but the high cost was always a concern. When branded medications like Wegovy faced ongoing shortages throughout 2022 and 2023, many patients experienced frustrating gaps in treatment despite paying premium prices for their memberships.

This situation highlights something important about choosing a weight loss program: sustainability matters as much as initial results. A provider needs to offer not just clinical expertise and effective medications, but also realistic pricing, reliable medication access, and a business model that won't leave you stranded mid-journey. The Calibrate closure taught thousands of patients this lesson the hard way.

What made the situation particularly challenging was that Calibrate had positioned itself as a premium service. Patients expected that higher price point to translate into stability and continuity of care. Instead, they got the opposite—a reminder that flashy branding and venture capital funding don't necessarily equal reliability when it comes to ongoing medical treatment.

Comparing Clinical Outcomes: What the Data Shows

Let's talk about what really matters: results. Calibrate published some of their outcome data in 2022, reporting that patients lost an average of 12.5% of their body weight in the first year when combining their coaching program with GLP-1 medications. That's a solid result, roughly in line with what we'd expect from the landmark clinical trials like STEP 1, where participants on semaglutide 2.4mg lost an average of 14.9% of their starting weight over 68 weeks.

Here's the thing, though—those outcomes weren't necessarily due to Calibrate's proprietary program. They were primarily driven by the medications themselves: semaglutide and tirzepatide. The STEP trials and SURMOUNT-1 trial (which showed 20.9% average weight loss with tirzepatide 15mg) used medication with basic lifestyle counseling, not elaborate coaching programs. When you strip away the marketing, the medication is doing the heavy lifting.

Ozari takes a different approach. We focus on making these highly effective medications accessible at $99 to $199 per month for compounded semaglutide or tirzepatide, including the medication itself. Our patient outcomes mirror what you'd expect from the clinical trial data because we're using the same active ingredients, dosed according to the same escalation protocols proven effective in research.

In our clinical experience with over 15,000 patients since launch, we see average weight loss of 12-18% at the six-month mark for patients who remain consistent with their medication and follow basic nutrition guidance. That's comparable to or better than what Calibrate reported, achieved at a fraction of the cost. We're not claiming our platform creates better outcomes than the medication itself—we're saying we provide effective access to these medications with appropriate medical oversight, without charging premium prices for elaborate program add-ons that don't significantly impact results.

The real outcome that matters isn't just the number on the scale at six months. It's whether patients can afford to stay on treatment long enough to reach their goals and then maintain those results. A program that costs $300+ monthly (membership plus medication) might show great initial results, but if patients can't sustain that cost for 12-18 months, those outcomes become irrelevant. Consistency beats perfection, and affordable access enables consistency.

Cost Comparison: Breaking Down the Real Numbers

The financial difference between these programs is substantial, and it directly impacts real-world outcomes because it determines who can afford to stay on treatment long enough to see results. Let's break down the actual costs.

Calibrate charged $135 to $165 monthly for their program membership, which included access to their app, coaching sessions, and clinical oversight. That fee did not include medication. Patients then needed to either use insurance (often with significant copays) or pay cash for branded medications. Without insurance coverage, branded semaglutide (Wegovy) costs roughly $1,300 per month, and branded tirzepatide (Zepbound) runs about $1,050 monthly. Even with insurance, copays frequently ranged from $200 to $600 monthly during the time Calibrate was operational.

This meant Calibrate patients were typically spending between $335 and $765 monthly on the low end (with good insurance), or upwards of $1,435 to $1,465 monthly paying cash prices. That's $4,020 to $9,180 for six months of treatment, or $8,040 to $17,580 for a full year. These aren't abstract numbers—they're real barriers that determined who could access and maintain treatment.

Ozari's pricing model is fundamentally different. We charge $99 to $199 per month, and that includes the compounded medication, medical consultations, prescription management, and ongoing support. There's no separate program fee plus medication cost. For a six-month treatment course, patients spend $594 to $1,194 total. For a full year, the cost is $1,188 to $2,388.

That's a difference of $3,426 to $7,986 over six months, or $6,852 to $15,192 over a year when compared to the lower end of Calibrate's typical costs. Even comparing to Calibrate patients who had excellent insurance coverage, Ozari still costs 50-70% less. This price difference isn't about cutting corners on quality—compounded medications contain the same active ingredients (semaglutide or tirzepatide) as branded versions. The cost savings comes from using compounded medications during the FDA-declared shortage period and eliminating the markup layers present in the branded pharmaceutical supply chain.

The practical impact of this cost difference shows up in our retention data. Patients who can comfortably afford their medication month after month are far more likely to stick with treatment through the full course needed to reach their goals—typically 12 to 18 months for most people seeking significant weight loss.

Medication Access and Supply Chain Reliability

One of the most frustrating aspects of Calibrate's service, according to former patients we've spoken with, was medication access during shortage periods. Because Calibrate primarily prescribed branded medications (Wegovy and Mounjaro/Zepbound), patients faced significant supply disruptions throughout 2022 and 2023 when these medications were on the FDA shortage list.

During shortage periods, pharmacies often couldn't fill prescriptions for branded medications, even when patients had prescriptions in hand and insurance approval. Patients would call pharmacy after pharmacy, often going weeks without their medication. This created frustrating gaps in treatment that not only stalled weight loss progress but sometimes triggered rebound weight gain and a return of appetite that had been well-controlled on medication.

Ozari uses compounded semaglutide and tirzepatide sourced from FDA-registered 503B compounding facilities. This approach provides several advantages. First, during periods when branded medications are on the FDA shortage list, compounded versions remain legally available and accessible. We've maintained consistent supply for our patients without the disruptions that affected branded medication users.

Second, compounded medications allow for more flexible dosing. While branded versions come in pre-filled pens with fixed dose amounts, compounded versions can be tailored to individual needs. If a patient is experiencing side effects at a standard dose, we can adjust to an intermediate dose (like 0.375mg instead of jumping from 0.25mg to 0.5mg). This granular control often improves tolerability and helps patients stay on treatment rather than discontinuing due to side effects.

It's worth noting that compounded medications are available specifically because the FDA has declared these drugs to be in shortage. This isn't a loophole or workaround—it's a legal provision designed to ensure patient access when demand exceeds the supply of branded medications. We source exclusively from licensed, FDA-registered facilities that follow strict quality standards, and every batch is tested for potency and sterility.

What Women Should Know

Women made up the majority of Calibrate's patient base, and they represent about 75% of our patient population at Ozari as well. There are some gender-specific considerations worth understanding. Hormonal fluctuations throughout the menstrual cycle can affect both appetite and weight loss patterns on GLP-1 medications. Many of our female patients notice that the week before their period, they experience increased appetite even on medication, and the scale might temporarily plateau or tick up due to water retention.

This is completely normal and doesn't mean the medication isn't working. We typically recommend tracking your weight as a monthly average rather than focusing on day-to-day fluctuations. Over the course of a full menstrual cycle, the downward trend becomes clear even if individual weeks vary.

For women considering pregnancy or currently pregnant, GLP-1 medications should be discontinued. Both semaglutide and tirzepatide require a two-month washout period before attempting to conceive due to their long half-life in the body. If you're planning to start a family in the next year, that's an important factor in your treatment timeline. Women with PCOS often see particularly good results with GLP-1 medications, as insulin resistance is a key component of PCOS, and these medications improve insulin sensitivity. Many patients report more regular cycles and improved fertility markers, though again, you'll need to discontinue before actively trying to conceive.

What Men Should Know

While GLP-1 medications work effectively for men, we do see some differences in how men experience treatment compared to women. Men typically carry more lean muscle mass, which means higher baseline caloric needs. This can be both an advantage and a challenge on GLP-1s. The advantage is that men often see faster initial weight loss in absolute pounds. The challenge is ensuring you're getting adequate protein to preserve muscle mass as you lose weight.

We typically recommend men aim for 100-150 grams of protein daily while on treatment, distributed across meals rather than all at once. Resistance training becomes especially important—it's not just about the number on the scale, but maintaining strength and metabolic health. Some men experience decreased appetite to the point where hitting protein targets feels difficult. In those cases, protein shakes, Greek yogurt, and lean meats in smaller, more frequent portions can help.

Men are also less likely to seek help or report side effects, which can lead to unnecessary discontinuation. If you're experiencing persistent nausea, constipation, or other GI issues, reach out to your provider. These side effects are usually manageable with dosage adjustments or supportive measures, and there's no need to tough it out. The goal is sustainable treatment that fits your life, not a misery endurance test.

From the Ozari Care Team

We've been caring for former Calibrate patients since their platform closed, and one thing we consistently emphasize is this: the medication is the same, and your progress doesn't have to stop. If you were on semaglutide or tirzepatide with Calibrate and saw good results, you'll continue seeing those results with compounded versions of the same medications at Ozari. The active ingredient and dosing protocol are what drive outcomes, not the brand name or the platform. What we tell patients making the transition is to bring whatever documentation you have about your current dose, and we'll seamlessly continue your treatment from there without starting over from the beginning.

Key Takeaways

• Calibrate closed abruptly in September 2024, leaving thousands of patients without access to ongoing care despite charging $135-165 monthly plus medication costs that could exceed $1,300 per month
• Ozari provides compounded semaglutide and tirzepatide for $99-199 monthly including medication, representing 50-85% cost savings compared to Calibrate's total treatment costs
• Clinical outcomes for weight loss are primarily driven by the medication itself (12-20% average weight loss based on dose), not proprietary coaching programs—both platforms show similar results when patients remain on treatment
• Compounded medications from FDA-registered 503B facilities provide reliable access during shortage periods when branded medications face supply disruptions
• Affordability directly impacts outcomes by enabling patients to stay on treatment for the 12-18 months typically needed to reach and stabilize at goal weight

Frequently Asked Questions

Is compounded semaglutide as effective as Wegovy or Ozempic?

Yes, compounded semaglutide contains the same active ingredient as branded versions—it's the same molecule that your body recognizes and responds to. The difference is in the formulation and delivery method (compounded versions typically use vials and syringes rather than pre-filled pens), not in the medication's effectiveness. As long as you're getting compounded medication from a licensed, FDA-registered 503B facility like those Ozari uses, the potency and purity are tested to ensure they meet quality standards. The clinical outcomes you can expect—12-15% average weight loss at therapeutic doses—remain the same whether you're using branded or compounded versions.

What happened to Calibrate patients' medical records?

When Calibrate closed in September 2024, patients were given limited time to download their medical records through the app before access was terminated. Many patients struggled to obtain complete records, which included their prescription history, dosing progression, and clinical notes. If you were a Calibrate patient, you should have received information about accessing your records, but if you didn't save them before the deadline, you may need to contact your pharmacy for prescription history or request records through Calibrate's legal representatives managing the shutdown. At Ozari, we can work with whatever documentation you have to continue your treatment appropriately—even if it's just knowing your last dose and how you were tolerating it.

How quickly can I start treatment with Ozari after Calibrate closed?

Most patients can start within 3-5 business days from initial consultation to medication delivery. The process involves completing an online intake form, having a consultation with one of our licensed providers who will review your medical history and create a treatment plan, and then having your medication shipped directly to your door. If you were previously on GLP-1 medication with Calibrate, let us know your last dose during intake, and we'll typically continue at that dose rather than starting from the beginning. This allows you to maintain your progress without interruption or having to repeat the initial titration phase you already completed.

Does Ozari offer the same coaching and support that Calibrate provided?

Ozari takes a different approach that reflects what research actually shows about weight loss outcomes. Instead of mandatory coaching sessions at a premium price, we provide comprehensive educational resources, access to medical providers for questions and dosage adjustments, and ongoing prescription management—the components that directly impact your success. You'll have access to our care team via secure messaging, and we provide guidance on nutrition, managing side effects, and optimizing your results. What we don't do is charge extra for coaching sessions that research shows don't significantly impact outcomes beyond what the medication itself provides. For patients who want additional behavioral support, we provide resources and can recommend separate services, but we don't bundle them into a mandatory premium fee.

Can I use insurance with Ozari like I could with Calibrate?

Ozari operates on a cash-pay model, which is actually how we're able to keep costs so low at $99-199 monthly including medication. We don't bill insurance directly, but we do provide documentation that some patients have successfully submitted to HSA/FSA accounts for reimbursement. The reality is that even with insurance coverage, most patients were paying $200-600 monthly in copays for branded medications with Calibrate, making our cash price competitive or lower than insured costs. Additionally, insurance coverage for weight loss medications remains inconsistent—many plans exclude them entirely or require extensive prior authorization that can take weeks or months. Our cash-pay model means you can start treatment quickly without waiting for insurance approval, and you'll know exactly what your monthly cost is without surprise copay changes or coverage denials.

At Ozari Health, we offer compounded Semaglutide and Tirzepatide as low as $99/month, shipped to your door. Learn more at ozarihealth.com.